Longdom Conferences

Scientific program

May 27, 2021    London, UK

Webinar on Virology Immunology

  • Home -
  • Scientific program

Coming soon...

Useful Links

News

R&D Blueprint and COVID-19

2020-12-04

The current COVID-19 pandemic is unprecedented, but the global response draws on the lessons learned from other disease outbreaks over the past several decades. As part of WHO’s response, the R&D Blueprint was activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus. The Blueprint aims to improve coordination between scientists and global health professionals, accelerate the research and development process, and develop new norms and standards to learn from and improve upon the global response. On 30 January 2020, following the recommendations of the Emergency Committee, the WHO Director-General declared that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC). World scientists on COVID-19 then met at the World Health Organization’s Geneva headquarters on 11–12 February 2020 to assess the current level of knowledge about the new virus, agree on critical research questions that need to be answered urgently, and to find ways to work together to accelerate and fund priority research to curtail this outbreak and prepare for those in the future.

The COVID-19 candidate vaccine landscape

2020-12-19

The COVID-19 candidate vaccine landscape database compiles detailed information on COVID-19 vaccine candidates in development. The landscape is updated regularly - twice a week (Tuesday and Friday, 17:00 CET). The landscape: provides summary tables of COVID-19 vaccine candidates in both clinical and pre-clinical development; provides analysis and visualization for several COVID-19 vaccine candidate categories; tracks the progress of each vaccine from pre-clinical, Phase 1, Phase 2 through to Phase 3 efficacy studies, provides links to published reports on safety, immunogenicity and efficacy data of the vaccine candidates; includes information on key attributes of each vaccine candidate; and allows users to search for COVID-19 vaccines through various criteria such as vaccine platform, dosage, schedule of vaccination, route of administration, developer, trail phase and clinical endpoints being measured in Phase 3.

Target Product Profiles for COVID-19 Vaccines

2021-01-19

The current global nCoV public health emergency underscores the need to accelerate the development of nCoV candidate vaccines. The Working Group on Target Product Profile for vaccines against COVID-19 aims to provide guidance from an end-to-end perspective. The objectives of this group are: To develop a global target product profile (TPP) for vaccines against COVID-19. The TPP will include preferred and minimally acceptable profiles for two vaccines: Human vaccine – for long term protection of persons at high ongoing risk of COVID-19 such as healthcare workers. Human vaccine – for reactive use in outbreak settings with rapid onset of immunity. To prepare and be available for the regular working group calls. To provide technical advice and support the WHO Secretariat through comments and or feedback from stakeholders.

Newsletter

© 2024 All Rights Reserved by Longdom